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ABSTRACT
The complement system is important in immunosurveillance against
tumors. However, malignant cells are usually resistant to complement-
mediated lysis. In this study, we examine the expression of factor H, an
inhibitor of complement activation, and factor H-like protein 1 (FHL-1),
its alternatively spliced form, in lung cancer. We also evaluate the poten-
tial effect of factor H/FHL-1 in the protection of lung cancer cells against
the activation of the complement cascade. By Northern blot analysis we
demonstrate a high expression of factor H and FHL-1 in most non-small
cell lung cancer cell lines, although neuroendocrine pulmonary tumors
(small cell lung carcinoma and carcinoid cell lines) had undetectable
levels. Western blot analysis of conditioned medium showed the active
secretion of factor H and FHL-1 by cells that were positive by Northern
blot. Expression of factor H/FHL-1 mRNA was also shown in a series of
non-small cell lung cancer biopsies by in situ hybridization. Interestingly,
many cultured lung cancer cells were able to bind fluorescence-labeled
factor H to their surfaces. Deposition of C3 fragments from normal
human serum on H1264, a lung adenocarcinoma cell line, was more
efficient when factor H/FHL-1 activity was blocked by specific antibodies.
Blocking factor H/FHL-1 activity also enhanced the release of anaphyla-
toxin C5a and moderately increased the susceptibility of these cells to
complement-mediated cytotoxicity. In summary, we demonstrate the ex-
pression of factor H and FHL-1 by some lung cancer cells and analyze the
contribution of these proteins to the protection against complement acti-
vation.
INTRODUCTION
Lung cancer is the leading cause of cancer deaths throughout the
world (1). The 5-year survival rates for lung cancer are 15% in all
developed countries and 5% in many developing countries. These
poor survival rates demand new strategies for early detection and
major improvements in therapy. New biological and molecular knowl-
edge of lung carcinogenesis has led to the proposal of new therapeutic
strategies against lung cancer. Some of these strategies are based on
monoclonal antibodies targeted to tumor-associated antigens that,
among other mechanisms, can initiate complement-dependent cell
lysis (2, 3). However, tumor cells seem to have mechanisms to
circumvent this complement-mediated immune response (4). It has
been suggested that human non-small cell lung cancer cells are
especially resistant to complement-mediated lysis as compared with
normal cells (5).
The complement system consists of a cascade of functionally
related proteins capable of causing cell lysis. This system plays a key
role in the elimination of non-self cells and the initiation of inflam-
matory response (6). The activation of the complement cascade is
highly controlled by several regulatory proteins that prevent comple-
ment activation. The alternative pathway of complement is spontane-
ously activated and requires specific protection mechanisms to restrict
the destructive effects of an uncontrolled activated system (7). Com-
plement factor H is a key inhibitor of the activation of the alternative
pathway. Factor H is a 150-kDa glycoprotein present in human
plasma, which is constitutively produced by the liver but is also
synthesized extrahepatically by mononuclear phagocytes, fibroblasts,
endothelial cells, mesangial cells, astrocytes, oligodendrocytes, and
neurons (8–10). Factor H is composed of 20 repetitive domains
termed short consensus repeats, each 60 amino acids in length.
Additionally, a 42-kDa protein produced by alternative splicing from
the factor H mRNA has also been found. This protein, named factor
H-like protein 1 (FHL-1), contains the first 7 domains of factor H and
4 additional amino acids at the COOH-terminal end (11). FHL-1
shares the complement regulatory functions of factor H. Both factor H
and FHL-1 bind to C3b, the key component for complement activa-
tion, destroying the C3 convertase. Factor H is also a necessary
cofactor for the inactivation of C3b by factor I. The ultimate result of
factor H activity is the inhibition of the alternative pathway of com-
plement (12–14). In addition to its regulation of complement activa-
tion, other functions have been found for factor H. It is a ligand for
L-selectin (15) and also binds to the integrin Mac-1 (CD11b/CD18),
enhancing the activation response of human neutrophils (16). Factor H
also induces the secretion of interleukin 1 by monocytes (17) and
acts as a chemotactic protein for these cells (18). Factor H binds to cell
surface components of several pathogens (19–23), inhibiting the
alternative pathway of complement and thus enhancing their patho-
genicity. Finally, factor H binds and increases the receptor-mediated
activity of adrenomedullin, a vasodilator and tumor-promoting pep-
tide (24).
Expression of factor H and FHL-1 has been demonstrated in cell
lines from several malignancies: glioblastomas, myosarcomas, neuro-
blastomas, and carcinomas from nasopharynge, ovary, cervix, blad-
der, and kidney (25–30). Ovarian tumors also produce factor H and
FHL-1 (29). Finally, a clinically approved immunoassay for the
detection of bladder cancer in urine is based in the quantification of
factor H or a factor H-related molecule (30).
The objective of our study was to determine whether factor H is
expressed in lung cancer, and if so, to investigate the contribution of
factor H to the resistance of the lung cancer cells to complement-
mediated cytotoxicity. We found that factor H and FHL-1 are ex-
pressed in many non-small cell lung cancer cell lines and non-small
cell lung cancer tumors. Factor H is also secreted to the extracellular
milieu and is able to bind to the tumor cell surface. Our results also
demonstrate that factor H and/or FHL-1 limit the activation of com-
plement on lung cancer cell membranes, although, in our experimental
conditions, not to the extent to fully justify the resistance observed in
lung cancer cells to complement-mediated lysis.
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MATERIALS AND METHODS
Lung Cancer Cell Lines and Biopsies. A range of lung cancer cell lines
from the American Type Culture Collection (Manassas, VA) was used. Cells
were grown in culture flasks (75 cm2) using RPMI 1640 with L-Glutamax (446
mg/ml) supplemented with 10% fetal bovine serum (FBS), 100 units/ml of
penicillin, and 100 g/ml of streptomycin (Invitrogen, Carlsbad, CA). Cell
lines included in the study were: small cell lung carcinomas (H69, H209,
H345, N417, H510, H82, and H187), adenocarcinomas (H23, H1264, and
H2087), bronchioloalveolar carcinomas (A549, H358, and H820), large cell
carcinomas (H460, H661, H1155, and H1385), squamous cell carcinomas
(H157 and H226), and carcinoids (H720 and H727). Lung carcinoma biopsies
were obtained at the Clı´nica Universitaria de Navarra (Pamplona, Spain) under
an institution-approved human tissue procurement protocol. Tumors consisted
of 3 squamous cell carcinomas and 5 adenocarcinomas (including 3 bronchi-
oloalveolar carcinomas). Samples were immersed in buffered formalin within
20 min from surgical resection. All of the samples were removed from the
fixative solution after 24 h. Tissues were embedded in paraffin and sectioned
(3 m thick).
Sera. Normal human serum, used as a source of complement, was freshly
prepared from healthy donors. Heat inactivated-normal human serum was
obtained by incubating normal human serum at 56°C for 30 min.
Factor H Purification and Labeling. Human complement factor H was
purified from plasma by liquid chromatography as described previously (31).
Final concentration was 0.9 mg/ml in PBS. Factor H was labeled using the
Alexa Fluor 488 Protein Labeling kit (Molecular Probes, Eugene, OR). Final
concentration of labeled factor H in PBS was 420 g/ml, and the labeling ratio
was 14.4 moles of dye per mol of factor H.
Production and Purification of Antifactor H Antibodies. Mouse hybri-
doma lines OX-23 and OX-24 (European Collection of Cell Cultures, Center
for Applied Microbiology and Research, Salisbury, United Kingdom) were
maintained in RPMI 1640 supplemented with 10% FBS and penicillin-strep-
tomycin. For production of OX-23 and OX-24 IgG1 monoclonal antibodies,
hybridomas were grown in a protein-free growth medium (CD Hybridoma
Medium, Invitrogen) from which antibodies were purified by ammonium
sulfate precipitation followed by affinity chromatography (HiTrap Protein G
MP, Amersham Pharmacia, Piscataway, NJ). Final concentration of both
monoclonal antibodies was 1.2 mg/ml in PBS. In addition, rabbit antifactor H
antibodies (Serotec, Raleigh, NC) were purified from sera by affinity chroma-
tography after coupling factor H to the column gel (UltraLink Biosupport
Medium, Pierce, Rockford, IL). Affinity purified polyclonal antibodies were
stored in PBS at 1 mg/ml. Immunoreactivity of both monoclonal and poly-
clonal antibodies was determined by ELISA and purity confirmed by SDS-
PAGE and Coomassie staining.
Northern Blotting. Total RNA was isolated from the cell lines using the
guanidine isothiocyanate and cesium chloride method (32). Fifteen micro-
grams of RNA were loaded per lane, run in 1% agarose gels containing 2.2
mol/L formaldehyde, blotted onto nitrocellulose membranes, and baked for 2 h
at 80°C. Equal loading and integrity of RNA were monitored by ethidium
bromide staining of the 28 S and 18 S subunits of rRNA. A PCR product (854
bp) of the human factor H cDNA (GenBank accession no. Y00716) was
generated using primers 5-GACACGGATGCATCTGGGAGTA-3 (sense)
and 5-CAATGGAACCAGATCGGGAATA-3 (antisense) and cloned into
the pCRII vector (Invitrogen). The insert was sequenced to validate the
integrity of the probe. The human factor H probe was generated from the
pCRII vector by digestion with EcoRI. Probe was labeled with [-32 P]dCTP
(3000 Ci/mmol; NEN Life Science Products, Boston, MA) using the Prime-it
RmT Random Primer Labeling kit (Stratagene, La Jolla, CA). Unincorporated
nucleotides were removed by MicroSpin G-50 Columns (Amersham Pharma-
cia Biotech). Hybridization was carried out overnight at 42°C in a hybridiza-
tion buffer containing 40% formamide (32). After stringency washes, blots
were exposed to X-ray films.
Western Blotting. Supernatants from cells grown in 100-mm cell culture
dishes (Corning Incorporated, Corning, NY) using 12 ml of RPMI 1640
without FBS for 24 h were concentrated 60-fold using centrifugal filter units
(Centricon YM-10, Millipore Corporation, Billerica, MA). Ten micrograms of
total protein were electrophoretically fractionated on 4–12% Bis-Tris gel
(Novex, San Diego, CA) under nonreducing conditions, transferred to a 0.45
m nitrocellulose membrane, and blocked with 5% fat-free dry milk in PBS.
The membrane was then incubated with antifactor H monoclonal antibody
OX-24 (1:2,000) and developed using the Lumi-Light Western Blotting kit
(Roche). Factor H and FHL-1 were used as positive controls. Recombinant
FHL-1 was kindly provided to F. C. by Dr. Peter Zipfel (Hans Knoell Institute
for Natural Products Research, Jena, Germany).
Factor H/FHL-1 Quantitation. A polystyrene 96-well plate (Corning)
was coated with 200 ng/well of purified rabbit antifactor H antibodies [in 50
l of 50 mM sodium bicarbonate (pH 8.3)] during 1 h at room temperature. The
plate was blocked overnight at 4°C with Tris-buffered saline, 1% bovine serum
albumin, and 0.1% Tween 20 (pH 7.4). After washing, 100 l of supernatants
(from cells grown in RPMI 1640 without FBS for 24 h) or standards (factor H
ranging from 1.5 to 200 ng/ml) were added in blocking buffer and incubated
for 2 hours at room temperature. After washing, 100 l of OX-23 monoclonal
antifactor H antibody (1:200) were added, and after 2-hour incubation at room
temperature the assay was developed using a goat antimouse antibody coupled
to horseradish peroxidase (1:1,000, Sigma-Aldrich, St. Louis, MO) and O-
phenylenediamine dihydrochloride (Sigma-Aldrich). The plate was read at
450 nm.
In situ Hybridization. The pCRII vector containing factor H cDNA was
linearized with SacI and XbaI and used as a template to synthesize digoxige-
nin-labeled sense and antisense riboprobes. After proteinase K treatment and
acetylation, hybridization was performed in a moist chamber at 58°C for 18
hours. After stringency washes, visualization of digoxigenin was performed
using an alkaline phosphatase-labeled antidigoxigenin antibody and nitroblue
tetrazolium/5-bromo-4-chloro-3-indolyl phosphate as substrate (Roche, Indi-
anapolis, IN). Sense probe was used as negative control.
Binding of Factor H to Lung Tumor Cells. Cells were detached from
culture dishes with 1 mM EDTA, washed once, and resuspended in binding
buffer (PBS, 1% bovine serum albumin, and 0.1% sodium azide). Cells (1 
105 in 50 l of binding buffer) were incubated with 2 l of labeled human
factor H for 30 min at 4°C. Cells were washed three times and analyzed on a
flow cytometer (FACSCalibur, Becton Dickinson) after the addition of pro-
pidium iodide. Cell Quest Pro software was used for data acquisition and
analysis. Data were collected as mean fluorescence intensity. For competition,
10 l of unlabeled human factor H or 10 l of polyclonal goat-antihuman
factor H serum (Quidel, San Diego, CA) were also added to the incubation.
Deposition of C3-Related Fragments. Cells were detached from culture
dishes with 1 mM EDTA, washed once, and resuspended in veronal buffer [1.8
mM barbital, 3.1 mM barbituric acid, 141 mM sodium chloride, and 0.5 mM
MgCl (pH 7.4)]. Cells (2  105 in 100 l) were incubated for 30 min at 37°C
with 100 l of normal human serum (diluted 1:8) or 100 l of normal human
serum (diluted 1:8) preincubated for 30 min at 4°C with monoclonal antibody
OX-23 or OX-24 at 0.6 mg/ml. After washing twice with binding buffer, cells
were incubated for 30 min at 4°C with a fluorescein isothiocyanate-conjugated
goat antihuman-complement C3 antibody (ICN Biomedicals Inc., Aurora, OH)
diluted 1:100 in a total volume of 50 l. Cells were washed twice and analyzed
by flow cytometry after the addition of propidium iodide. Data were collected
as mean fluorescence intensity.
Determination of C5a Production. Cells were processed and treated as
described in the previous paragraph. Generation of C5a was quantified in
supernatants after incubation with normal human serum, heat inactivated-
normal human serum, or normal human serum with monoclonal antibodies
OX-23 and OX-24. Quantitation was performed using the Human C5a ELISA
kit (BD Biosciences PharMingen, San Diego, CA) following the manufactur-
er’s instructions.
Complement-Mediated Cytotoxicity. When a 1:16 final dilution of serum
was tested, cells were processed and treated as described above. For experi-
ments with serum diluted 1:8, a double concentration of serum and monoclonal
antibodies was used. Cells were analyzed by flow cytometry after the addition
of propidium iodide. Data were collected as mean fluorescence intensity.
Statistical Analysis. Data obtained from C3 deposition, C5a quantitation,
and complement-mediated cytotoxicity were analyze by Student’s t test. A
P  0.05 was considered statistically significant.
RESULTS
Factor H and FHL-1 Expression in Lung Cancer. We first
compared the amount of factor H and FHL-1 mRNA in lung cancer
cell lines with that in cancer cell lines from other origins: breast,
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colon, prostate, and ovary. Northern blot analysis revealed that factor
H and FHL-1 mRNA expression was much higher in lung tumor cell
lines than in cell lines from other origins (Fig. 1), although one of the
lung cancer cell lines (H209) was negative. We next examined mRNA
levels in a panel of 18 lung tumor cell lines from the main types of
lung cancer (Fig. 2A). Many of them expressed factor H and FHL-1
mRNA, although the amount of mRNA was highly variable between
cell lines. In particular, we did not detect any factor H or FHL-1
mRNA in any small cell lung carcinoma cell line. To confirm the
production of factor H and FHL-1 by lung cancer cell lines, we
analyzed the presence of both proteins in whole cell lysates. We used
most of the cells present in the Northern blot analysis and included
some additional cell lines. In these extracts, we were not able to detect
factor H or FHL-1 by Western blotting (data not shown). We then
evaluated the possibility that both proteins were secreted to the
extracellular medium. To avoid interferences with the presence of
factor H in FBS, media were obtained from cells cultured during 24 h
in serum-free RPMI 1640. By Western blot analysis we were able to
detect factor H and FHL-1 in the serum-free conditioned media of
many non-small cell lung cancer cell lines, confirming that these cells
produce and secrete factor H and FHL-1. Fig. 2B shows a represent-
ative Western blot in which expression of factor H can be observed in
most non-small cell lung cancer cell lines. FHL-1 was observed in
some non-small cell lung cancer cell lines (Fig. 2B). Longer exposure
times of the blot also revealed FHL-1 in cell lines H1264, H157, and
H226 (data not shown). In contrast, factor H and FHL-1 were unde-
tectable in small cell lung carcinoma cells. Similar findings were
observed for the neuroendocrine-like carcinoid tumor cell lines H720
and H727. By ELISA, we quantified the levels of factor H/FHL-1
secreted by these cells (Table 1). Globally, there was a high concord-
ance between factor H and FHL-1 mRNA and protein levels for each
cell line. These data suggest that factor H and FHL-1 are expressed at
high levels by many non-small cell lung cancer cell lines but are not
stored intracellularly. Rather, they are efficiently secreted to the
extracellular medium.
Fig. 1. Northern blot analysis showing the expression of factor H and FHL-1 in lung
cancer cell lines and cancer cell lines from other tissue origins. Fifteen micrograms of total
RNA were loaded per lane, and ethidium bromide staining of 18S and 28S rRNA was used
to ensure equal loading and RNA integrity.
Fig. 2. Expression of complement regulators
factor H and FHL-1 in small cell lung carcinoma
(SCLC) and non-small cell lung carcinoma cell
lines. A, Northern blot analysis in which 15 g of
total RNA were loaded per lane. Ethidium bromide
staining of 18S and 28S rRNA was used to ensure
equal loading and RNA integrity. B, Western blot
analysis of the presence of factor H and FHL-1
proteins in the extracellular medium. Samples are
serum-free conditioned media (10 g of total pro-
tein) from lung cancer cell lines that had been
conditioned for 24 hours. Four nanograms of puri-
fied factor H and recombinant FHL-1 were used as
positive controls.
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We then determined the expression of factor H and/or FHL-1 in
lung tumors in vivo. Considering that factor H and FHL-1 are rapidly
secreted to the extracellular medium and no detectable amounts of the
proteins are stored into the cultured lung cancer cells, we decided to
use in situ hybridization to localize the mRNA of these factors in lung
tumor biopsies. We analyzed paraffin-embedded lung tumors, adeno-
carcinomas, and squamous cell carcinomas using an RNA probe that
recognizes both factor H and FHL-1 mRNA. In agreement with our
previous data with cell lines, we observed cytoplasmic accumulation
of factor H and/or FHL-1 mRNA in most lung cancer tumors (6 of 8).
mRNA levels varied between positive tumors (Fig. 3, A, D, and G). In
all of the cases the sense probe was used as a negative control (Fig. 3,
B, E, and H).
Binding of Factor H to Lung Tumor Cell Lines. Because factor
H and FHL-1 are actively secreted to the extracellular medium, we
wanted to determine whether lung tumor cells were able to bind factor
H to their surfaces. Cells were incubated with Alexa Fluor 488-labeled
factor H. After thorough washes to remove the unbound protein, flow
cytometry analysis showed marked binding of fluorescent factor H to
many cell lines (H69, H209, H82, H187, H23, H1264, A549, and
H460). As a representative example, Fig. 4 shows the binding of
labeled factor H to H1264 cell surface. Specificity of the binding was
demonstrated by competition with unlabeled factor H or an antifactor
H polyclonal antiserum. We obtained a complete competition when
the antiserum was used (Fig. 4B), whereas unlabeled factor H did not
completely compete the binding (Fig. 4A). This suggests the presence
of both specific and nonspecific binding to the cell surface. In our
analysis we also found cell lines with very little and probably non-
specific binding of factor H (H345, H661, and H727). These results
suggest that some lung cancer cells that are able to produce and
secrete factor H have also the ability to bind soluble factor H from the
fluid phase. Additionally, other lung cancer cell lines that do not
express factor H are also able to bind it to their surface (i.e. H82).
H1264, a cell line that both produces and binds factor H, was chosen
to additionally analyze the activation of the alternative pathway of
complement on lung cancer cells.
Deposition of C3-Related Fragments on the Surface of H1264
Lung Cancer Cells. In view of our results showing the ability of cell
line H1264 to bind factor H, we evaluated whether the recruitment of
factor H by these lung cancer cells affects the activation of comple-
ment. A key event in the activation cascade of complement is the
deposition of C3b on the cell surface. Factor H causes the degradation
of C3b and, therefore, the inactivation of the C3 convertase C3bBb.
The inactivation of C3b prevents the deposition of additional C3b
molecules in the cell membrane, which is mediated by this convertase.
For that reason, the deposition of C3 fragments on the cell surface is
a good indicator of activation of the alternative pathway of comple-
ment. In our study, we used a polyclonal antibody that recognizes C3
and C3 fragments such as C3b and inactive C3b, one of the products
from C3b cleavage. The minimal activation of complement by lung
cancer cells has already been described (5). We confirmed this ob-
servation with some of our lung cancer cell lines. In the presence of
normal human serum diluted 1:16 very little C3-fragment deposition
by the alternative pathway was observed in all of the lung cancer cell
lines tested (H1264, A549, H82, and H661). Fig. 5, A and C, shows
Table 1 Expression of factor H/FHL-1 by lung cancer cell lines
Cell line* Conditioned media (pg/g total protein)
H1264 7  1.7†
H2087 52.2  2.9
A549 38.7  11
H358 312.3  71.5
H460 50.6  6.2
H157 8.1  3.4
H226 4.7  2.3
* Small cell lung carcinoma cell lines, H23, H661, H1385, H727, and H720 had
undetectable levels.
† Data represent mean  SD (n  2).
Fig. 3. In situ hybridization detecting the presence of
factor H mRNA in sections of non-small cell lung carci-
noma biopsies. A digoxigenin-labeled antisense probe was
used to detect the expression of factor H/FHL-1 mRNA (A,
D, and G). The figure shows examples of tumors with
different levels of factor H/FHL-1 expression. A, squamous
cell carcinoma with a strong cytoplasmic expression. D,
adenocarcinoma with moderate labeling. G, squamous cell
carcinoma with very low expression. The sense probe was
used in serial sections as a negative control (B, E, and H).
Hematoxylin and eosin staining is also shown for each
tumor to assess their morphological features (C, F, and I).
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the deposition of C3-fragments in H1264 cells in the presence of
normal human serum (diluted 1:16) when compared with the deposi-
tion in the absence of serum or in the presence of heat inactivated-
normal human serum. To study the effect of the inhibition of factor H
activity on this deposition, we used the monoclonal antibodies OX-24
and OX23. OX24 is an antibody that inhibits the binding of factor H
and FHL-1 to surface-bound C3b (33). In contrast, OX-23 is an
antibody against factor H and FHL-1 that binds to a different epitope
from OX-24 and does not affect the binding of factor H and FHL-1 to
surface-bound C3b (33). When H1264 cells were incubated with
normal human serum in the presence of OX-24, the deposition of C3
or related fragments increased significantly (P  0.021; Fig. 5, B and
C). When the same experimental conditions were carried out in the
presence of OX-23 antibody no changes were observed when com-
pared with normal human serum alone (P  0.458). The difference in
C3 deposition between the treatment with OX-24 and OX-23 also
reached statistical significance (P  0.027). These data suggest that
the activities of factor H and/or FHL-1 protect these lung cancer cells
against the deposition of C3-related fragments. When the same ex-
periments were carried out with cell line H661, which does not show
a significant binding of factor H, we observed a minimal increase of
the deposition of C3-fragments in the presence of normal human
serum (diluted 1:16) when compared with the deposition in the
absence of serum or in the presence of heat inactivated-normal human
serum. However, neither OX-24 nor OX-23 affected this deposition
(data not shown), suggesting that in cell lines unable to bind factor H,
blockade of factor H activity does not modify C3 deposition on their
membranes.
Control of Anaphylatoxin C5a Production by Factor H on
H1264 Lung Cancer Cells. C3 convertase activity leads to the for-
mation and activation of C5 convertases, which cleave C5 in two
fragments: cell-bound C5b and C5a. C5a, a potent anaphylatoxin and
chemotactic factor, is important for initiation and maintenance of
inflammatory responses upon complement activation. We have shown
that factor H blockade by the monoclonal antibody OX-24 augments
the deposition of C3-related fragments and that this deposition may be
the result of an increase in C3 convertase activity. Therefore, we were
interested in evaluating whether this increase in C3 convertase activity
was followed by an increase in C5 convertase activity and a release of
C5a. For that purpose we determined the concentrations of C5a
released after activation of the alternative pathway of complement on
H1264 cells. As expected, incubation of H1264 cells in the presence
of normal human serum produced a moderate increase of C5a levels
in the medium: 22.8  2.6 pg/ml versus 13.3  0.6 pg/ml in the
medium from cells incubated with heat inactivated-normal human
serum. When cells were incubated with normal human serum in the
presence of OX-24 the release of C5a increased significantly
(52.8  3.2 pg/ml; P  0.0003). When the same experimental
conditions were carried out in the presence of OX-23 antibody no
significant changes were observed when compared with normal hu-
man serum alone (32.5  3.4 pg/ml; P  0.063). These results
suggest that the presence of factor H and/or FHL-1 inhibits the release
of C5a after activation of the complement alternative pathway.
Complement-Mediated Cytotoxicity on H1264 Lung Cancer
Cells. We have demonstrated that the binding of factor H and FHL-1
to lung cancer cells inhibits the deposition of C3 fragments. Among
other immunological implications, this deposition should affect the
susceptibility of these lung cancer cells to complement-mediated
cytotoxicity. To confirm this hypothesis, we analyzed the effect of
factor H neutralization on complement-mediated cytotoxicity of
H1264 cells. Factor H activities are primarily associated with the
inhibition of the alternative pathway of complement (12–14). There-
fore, we set up the conditions for the evaluation of the cytotoxic effect
of the alternative pathway of complement on H1264 cells. All of the
experiments were conducted in the presence of Mg2 and in the
absence of Ca2 to avoid the activation of the classical pathway.
Complement-mediated cytotoxicity was determined by flow cytom-
etry using propidium iodide uptake as an indicator of damaged cells.
To distinguish between nonspecific and complement-mediated cell
deaths we used heat inactivated-normal human serum as a control.
The number of propidium iodide-positive cells in the presence of
normal human serum minus the number of positive cells in the
presence of heat inactivated-normal human serum was considered the
number of cells specifically attacked by complement. When treated
with normal human serum diluted 1:16, 5% of H1264 cells were
killed by complement, indicating that these cells are highly resistant to
complement-mediated cytotoxicity. When factor H/FHL-1 were neu-
tralized by monoclonal antibody OX-24 the sensitivity of H1264 cells
to complement-mediated cytotoxicity increased moderately when
compared with an incubation with normal human serum alone or
normal human serum in the presence of OX-23 (P 0.031 and 0.004,
respectively; Fig. 6). The treatment with the monoclonal antibody
OX-23 did not modify significantly the viability of the cells
(P  0.058), although a small increase in viable cells was observed.
The same set of experiments was carried out with serum diluted 1:8.
In these conditions, approximately the same number of cell was killed
by complement. When factor H and FHL-1 were neutralized by
monoclonal antibody OX-24 the cytotoxicity increased almost 3-fold
Fig. 4. Flow cytometry analysis of the binding of fluorescent factor H (FH*) to H1264
cell surface. Specificity in the binding of labeled factor H to H1264 cells is shown by
competition with 10 l of unlabeled factor H (A) or 10 l of antiserum against factor H
(B). Factor H binding is indicated by an increase in intensity in the green channel.
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when compared with an incubation with normal human serum alone
or normal human serum in the presence of OX-23 (P  0.012 and
0.023, respectively; Fig. 6). Therefore, in these conditions, the block-
age of factor H activity had a more pronounced effect on cytotoxicity
than when serum diluted 1:16 was used. The treatment with the
monoclonal antibody OX-23 did not modify the viability of the cells
(P  0.904).
DISCUSSION
Alterations on membrane proteins associated to cellular transfor-
mation mark tumor cells for immune recognition. Transformed cells
can escape immune surveillance by developing inhibitory mecha-
nisms that provide resistance to immunological recognition and sub-
sequent attack. Both experimental and clinical studies indicate that
complement activation can play an important role in the immune
surveillance against tumors. However, tumor cells exploit several
strategies to circumvent the immune response (4). One of the better
understood protective mechanisms against immune surveillance is the
expression of membrane-associated complement regulatory proteins
such as CD55 (decay-accelerating factor), CD46 (membrane cofactor
protein), and CD59. Many current hypotheses propose that expression
of these proteins on the neoplastic cell membrane protects tumors
from complement activation (34–37).
In lung carcinomas, immunohistochemical analysis has revealed
expression of CD55, CD46, and CD59 (38). Additionally, lung tumors
show minimal deposition of C3b and no activation of the lytic mem-
brane attack complex. In vitro studies have confirmed that lung cancer
cell lines are extremely resistant to complement-mediated lysis, and
this resistance is much higher than that observed in normal cells such
as human nasal epithelium primary cell cultures (5, 39). Besides, lung
cancer cell lines have the ability of limiting the activation of comple-
ment in their cell membrane and express high levels of cell membrane
complement inhibitory proteins (5). For these reasons, it was sug-
gested that membrane-associated complement regulatory proteins
may act as mediators of lung cancer resistance to complement acti-
vation (38). However, neutralizing antibodies against CD46 and
CD59 are not effective in increasing the susceptibility to complement-
mediated lysis (5), whereas the same antibodies are very effective in
facilitating complement-mediated lysis of noncancer nasal epithelial
cells (39). This suggests the existence of alternative mechanisms that
would explain the resistance to complement activation in lung cancer.
In our study, we show the expression and binding of factor H to some
lung cancer cells and analyze its implications in the control of com-
plement activation and the protection from complement-mediated
lysis.
To date, little evidence for the role of factor H in the resistance of
Fig. 5. Effect of factor H and/or FHL-1 in the deposition of C3-related fragments. C3 deposition was determined by flow cytometry using a polyclonal antibody that recognizes
C3 and C3 fragments and is indicated by an increase in intensity in the green channel. Graphs in A and B are representative examples of the repeated experiments. A, deposition of
C3-related fragments on H1264 cells incubated with normal human serum (NHS) diluted 1/16, or heat-inactivated normal human serum (HI-NHS) at the same dilution. Incubation
without NHS is used as control. B, deposition of C3-related fragments on H1264 cells incubated with NHS (diluted 1/16) in the presence of antifactor H antibodies OX-24 and OX-23.
C, graph representing mean from the results obtained in three independent experiments; bars, SE. Data were analyzed as the ratio between the mean fluorescence intensity for
treatments and the mean fluorescence intensity for the control (incubation of the cells without NHS). *, P  0.05; n.s., not significant.
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tumor cells against complement damage has been reported. H2 glio-
blastoma cells are exceptionally resistant to complement-mediated
lysis but, although these cells strongly expressed CD59, CD46, and
CD55, a combined neutralization of these molecules does not increase
their sensitivity to complement killing (40, 41). It has been demon-
strated that H2 cells also produce factor H and FHL-1 and are able to
bind them, promoting C3b cleavage. Antifactor H monoclonal anti-
bodies enhance cell death (from 5% to 15%), confirming that factor H
(or FHL-1) is involved in the complement resistance of this cancer
cell line (40). In SK-MEL-93–2, a human melanoma cell line, factor
H is the dominant factor regulating the inactivation of cell-bound C3b
and is involved in the control of the classical pathway of complement
(42). An antifactor H antibody also enhances complement-mediated
killing of Raji cells, a cell line obtained from a Burkitt’s lymphoma
(43). Members of the SIBLING family can protect murine erythro-
leukemia and human myeloma and breast cancer cells from comple-
ment attack, likely by sequestration of factor H to the cell surface (44,
45). Factor H and FHL-1 are highly expressed by ovarian carcinomas,
and both proteins are abundantly present in ascites from these tumors
(29). By in situ hybridization, we have now demonstrated that non-
small cell lung cancer primary tumors also express complement factor
H mRNA.
In the present study, we have also shown that most non-small cell
lung cancer cell lines constitutively produce complement factor H and
FHL-1. Immunoblotting analysis has shown that these non-small cell
lung cancer cell lines also secrete factor H and FHL-1 into the
medium. Factor H production exceeded that of FHL-1 at both mRNA
and protein levels. This is different from what has been described in
normal lung, where there exists a predominant expression of the
1.8-kb mRNA (FHL-1) over the 4.3-kb mRNA (factor H), but it is
similar to what is observed in the liver, in which the 4.3-kb species is
more abundant (46, 47). Another interesting observation from our
study is the absence of factor H/FHL-1 mRNA and protein expression
in small cell lung carcinoma cell lines. In parallel to our findings with
small cell lung carcinoma cell lines, the two carcinoid cell lines
included in our study (H720 and H727) also lack factor H/FHL-1
expression, suggesting a phenotypic correlation between the expres-
sion of these proteins and the neuroendocrine differentiation of the
tumors. Consistent with this proposed relationship, two of the four
non-small cell lung cancer cell lines that lack factor H/FHL-1 expres-
sion (H1155 and H1385) have neuroendocrine features as well (48).
Complement can be activated via three different pathways: the
classical, the alternative, and the lectin pathway. Activation of C3 by
cleavage to C3b is a critical event in all three of the complement
fixation processes. In the alternative pathway, spontaneously gener-
ated C3b molecules attach to cell surface molecules and generate a C3
convertase, a complex that catalyzes the cleavage of C3 to C3b. As the
convertase progressively releases increasing amounts of C3b, more
C3 convertase can be assembled, and, thus, an amplification loop is
established. This leads to the accumulation of C3b on the cell mem-
brane, which initiates the complement cascade and ultimately ends in
cell lysis. This cascade of complement activation is tightly regulated.
In many cells, complement inhibitors promote the dissociation of the
convertase and/or the cleavage of C3b to inactive fragments such as
inactive C3b. Our study demonstrates that in the presence of normal
human serum there is a limited deposition of C3 fragments in lung
cancer cell membranes, a deposition insufficient to trigger cell death.
These results are in agreement with the minimal deposition of C3b
and the absence of activation of the lytic membrane attack complex
that has been reported for several types of lung carcinomas (38). As
demonstrated in our studies, factor H is involved in the control of the
amount of C3 deposited on the cell. Our results suggest that in some
malignant lung cells there is a spontaneous deposition of C3 that is
rapidly degraded to inactive C3b due in part to the presence of factor
Fig. 6. Susceptibility of H1264 lung cancer cell lines to
complement mediated cytotoxicity after neutralization of fac-
tor H/FHL-1 activity. H1264 cells were incubated with normal
human serum (NHS) or heat-inactivated normal human serum
(HI-NHS; control), and the number of dead cells was deter-
mined as propidium iodide-positive cells found in NHS-treated
cells minus the ones found in HI-NHS-treated cells. A gate was
established for the specific selection of these cells. A, repre-
sentative examples of the analysis of cells damaged by com-
plement, using NHS diluted 1/16 or 1/8, in the absence or
presence of the antifactor H neutralizing antibody OX-24 (note
the different scales on the Y axis of the two examples). B,
graphs representing the effect of the neutralization of factor
H/FHL-1 on complement-mediated cytotoxicity. Data are pre-
sented as fold change in the number of dead cells using NHS
as the reference value. Each value represents mean from at
least three independent determinations; bars, SE. *,
P  0.05; **, P  0.001; n.s., not significant.
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H on the cell membrane. When factor H activity is impaired by a
specific neutralizing antibody, C3b formed by spontaneous low-level
activation of C3 is not cleaved, and the amplification loop is initiated.
This can be detected as a higher deposition of C3-related fragments on
the cell membrane. Some experimental data suggest that in lung
cancer this effect is not carried out by membrane-associated comple-
ment regulatory proteins (CD46, CD55, and CD59), because cell
membrane adsorption of C3-fragments is not affected by neutraliza-
tion of these proteins (5). However, more work is needed to confirm
this point, especially considering that the protection mediated by
factor H would only be possible in cells that are capable of binding
this protein.
In our experiments, it is not possible to determine whether the
observed effects are due to factor H, FHL-1, or both. The two proteins
are highly expressed by some lung cancer cells, and the neutralizing
antibody used to analyze this protective effect may block the activities
of both proteins. As indicated previously, the expression of FHL-1
mRNA in normal lung is higher than that of factor H mRNA (46, 47),
whereas factor H is more abundant in lung tumor cell lines. The
preferential presence of factor H over FHL-1 in lung cancer differs
from what has been observed in glioblastoma and ovarian tumors,
where the predominant form is FHL-1 (29, 40). Our data also show
that factor H can bind to the cell membrane of some lung cancer cells,
but nothing is known about the binding properties of FHL-1.
Although we have observed an increase in C3 deposition and C5a
release after blocking factor H, in our studies, the activation of the
complement cascade led to a modest increase in complement-medi-
ated cytotoxicity. This paradox may be explained by several reasons.
On the one hand, our results may reflect a limited role of factor H in
regulating complement-mediated cytotoxicity on lung cancer cells,
suggesting that other inhibitory molecules are involved in resistance
to complement attack. However, on the other hand, our experimental
design may mask some of the potential effects of factor H on cyto-
toxicity. In our study we have only focused on the alternative pathway
of complement fixation, whereas in the in vivo setting of human
carcinogenesis, factor H and FHL-1 could potentially block all three
of the complement pathways. Additionally, even in the absence of
lysis, an increase of C3 fragments in the cell surface can enhance the
sensitivity of the tumor cells to be attacked by activated macrophages
(49), natural killer cells (50), and lymphocytes (51). Finally, upon
activation of C3 in our cells, the complement cascade of proteolytic
enzymes releases the anaphylatoxin C5a, and likely C3a and C4a.
These fragments exert various biological functions important to the
initiation and maintenance of an inflammatory process. In conclusion,
in a biological scenario, the control of C3 deposition, in this case by
factor H, may prevent the establishment of an important immune
response against the tumor. Taking this into account, it is still prema-
ture to state the real implication of this protein in the ability of human
lung tumors to evade in vivo immune surveillance.
It should also be considered that we have focused our functional
studies in the implication of factor H in the resistance to complement
activation and more particularly on the control of the alternative
pathway of complement. However, overexpression of factor H by
some lung cancer cells may also have a profound impact on tumor
growth through other additional mechanisms. For example, overex-
pression of factor H may have consequences in the regulation of the
activities of the tumor growth factor adrenomedullin. Adrenomedullin
is a 52 amino acid peptide with important tumor-promoting activities
(52, 53). Adrenomedullin, together with its receptor, is expressed by
lung carcinomas (54, 55) and mediates lung cancer cell growth (56),
angiogenesis, tumor cell migration, and survival (57). Factor H binds
to adrenomedullin and is able to increase its receptor-mediated activ-
ity (24). In this context, the expression of factor H by lung tumors may
regulate adrenomedullin tumor survival capabilities, thus augmenting
cancer progression.
In conclusion, in this study we show that several human non-small
cell lung cancer cells constitutively express and secrete complement
factor H and FHL-1. In addition, our results show that tumor cells that
bind factor H to their surface can prevent C3b accumulation upon
their cell membranes, although in our experimental conditions this
effect seems to be insufficient to fully explain the high resistance of
these cells to complement-mediated lysis. These results warrant ad-
ditional studies to evaluate the relevance of these and other comple-
ment regulatory proteins in in vivo immune surveillance. The eluci-
dation of these mechanisms would undoubtedly help to design
efficient complement-mediated immunotherapies against human
cancer.
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